Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

LONDON, June 4, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., (Hikma) offered the following comments on today's unanimous decision by the Supreme Court of the United States effectively ending Amarin's patent infringement litigation against the company.

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Thu, 04 Jun 2026 17:39:00 -0400

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

Mon, 08 Dec 2025 16:13:00 -0400

Ready-to-use sepsis therapy marks new advancement in time-critical treatment

LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN™ (vancomycin injection, USP).¹ TYZAVAN™ is offered in pre-filled ready-to-use bags that will help hospitals, pharmacists, doctors, and nurses treat patients faster, more easily, and with reduced risk. This is another example of how Hikma is using its capabilities as a leading generic pharmaceutical company to serve the growing needs

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

Mon, 08 Dec 2025 16:13:00 -0400

Ready-to-use sepsis therapy marks new advancement in time-critical treatment

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

Mon, 08 Dec 2025 16:13:00 -0400

Ready-to-use sepsis therapy marks new advancement in time-critical treatment

StreetInsider.com News Articles

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US